Journal of Chemical and Pharmaceutical Research

ABSTRACT: The present work focuses on the development of hydrodynamically balanced delivery system of loratadine as a single unit floating capsules. Sustained release floating capsules for loratadine were fabricated using drug:polymer ratio of 1:4. The hydrocolloids were used in different proportions using 32 full factorial design and formulations were prepared. These formulations were optimized on the basis of buoyancy, matrix integrity, duration of floating and in vitro drug release. All the nine formulations showed good buoyancy and matrix integrity. The duration of floating was more than 12 h for all formulations. In vitro drug release study of these formulations indicated controlled release of loratadine and about 90 percent drug was released at the end of 12 h. Further details @ http://www.jocpr.com/ For more details @ http://www.jocpr.com/articles/formulation-and-invitro-evaluation-of-floating-capsules-ofloratadine.pdf

ABSTRACT: Two innovative, new, simple and low cost UV-spectrophotometric and first order derivative methods were developed and validated for estimation of Galantamine Hydrobromide in bulk drug and tablet dosage form. Galantamine Hydrobromide was estimated at 289 nm in Distilled Water. In first order derivative, it showed amplitude at 284.8 nm and λminima = 290.4 nm with 286.4 nm as zero crossing point (ZCP). In both the methods linearity was found to be in the range of 20-100 µg/ml; for UV spectrophotometric method (y = 0.007x - 0.002, r² = 0.999) and for first order derivative spectrophotometric method (Y=0.0012 x+0.00045; r2=0.999), respectively. These methods were analyzed and validated for various validation parameters according to USP guidelines. The quantitation limits were found to be 0.50 and 1.54 µg/ml, for UV-Spectrophotometric method and 3.3 and 10 µg/ml for the 1st order derivative method. The proposed methods were successfully applied for the determination of Galant...